SectorPharmaceutical
Established Date30/09/2015
Listing Date05/02/2021
ExchangeNASDAQ Stock Exchange
Full-time Employees129
Fiscal Year Ends31/12
Security TypeCommon stock
Office addressEmmy Noetherweg 2, 2333 BK Leiden, The Netherlands
Business
IntroductionPharvaris N.V. was incorporated in the Netherlands on September 30, 2015. The Company is a clinical-stage biopharmaceutical company focused on the development of deucrictibant, an oral small molecule bradykinin B2 receptor antagonist, for the treatment of hereditary angioedema. Its R&D pipeline includes immediate-release capsules for on-demand treatment and sustained-release tablets for prevention, both of which have completed Phase 2 and Phase 3 trials.
